A focus on intra-abdominal infections
1Department of Surgery, Macerata Hospital - Via Santa Lucia 2, 62100 Macerata - Italy. m.sartelli@virgilio.it.
Abstract:
Complicated intra-abdominal infections are an important cause of morbidity and are frequently associated with poor prognosis, particularly in higher risk patients.Well defined evidence-based recommendations for intra-abdominal infections treatment are partially lacking because of the limited number of randomized-controlled trials.Factors consistently associated with poor outcomes in patients with intra-abdominal infections include increased illness severity, failed source control, inadequate empiric antimicrobial therapy and healthcare-acquired infection.Early prognostic evaluation of complicated intra-abdominal infections is important to select high-risk patients for more aggressive therapeutic procedures.The cornerstones in the management of complicated intra-abdominal infections are both source control and antibiotic therapy.The timing and the adequacy of source control are the most important issues in the management of intra-abdominal infections, because inadequate and late control of septic source may have a negative effect on the outcomes.Recent advances in interventional and more aggressive techniques could significantly decrease the morbidity and mortality of physiologically severe complicated intra-abdominal infections, even if these are still being debated and are yet not validated by limited prospective trials.Empiric antimicrobial therapy is nevertheless important in the overall management of intra-abdominal infections. Inappropriate antibiotic therapy may result in poor patient outcomes and in the appearance of bacterial resistance.Antimicrobial management is generally standardised and many regimens, either with monotherapy or combination therapy, have proven their efficacy. Routine coverage especially against Enterococci and candida spp is not always recommended, but can be useful in particular clinical conditions. A de escalation approach may be recommended in patients with specific risk factors for multidrug resistant infections such as immunodeficiency and prolonged antibacterial exposure.Therapy should focus on the obtainment of adequate source control and adequate use of antimicrobial therapy dictated by individual patient risk factors. Other critical issues remain debated and more controversies are still open mainly because of the limited number of randomized controlled trials.
Insights
Complicated intra-abdominal infections require prompt source control and appropriate antibiotic therapy. Early risk assessment is crucial for guiding aggressive treatment in high-risk patients to improve outcomes.
Area of Science:
- Infectious Diseases
- Surgical Infections
- Critical Care Medicine
Background:
- Complicated intra-abdominal infections (IAIs) contribute significantly to patient morbidity and mortality.
- Limited randomized-controlled trials hinder the development of evidence-based treatment guidelines for IAIs.
- Factors like illness severity, failed source control, and inadequate antimicrobial therapy predict poor outcomes.
Purpose of the Study:
- To emphasize the critical role of early prognostic evaluation in identifying high-risk patients with IAIs.
- To highlight the cornerstones of IAI management: source control and antibiotic therapy.
- To discuss recent advances and ongoing debates in IAI treatment strategies.
Main Methods:
- Review of current literature and clinical practice guidelines for complicated intra-abdominal infections.
- Analysis of factors associated with poor outcomes in IAI patients.
- Discussion of the impact of source control timing and adequacy.
- Evaluation of empiric antimicrobial therapy strategies and resistance concerns.
Main Results:
- Source control, both in timing and adequacy, is paramount for favorable outcomes in IAIs.
- Inadequate or delayed source control negatively impacts patient prognosis.
- Empiric antimicrobial therapy must be appropriate to prevent poor outcomes and resistance.
- De-escalation strategies may be beneficial for specific patient groups.
- Recent aggressive techniques show promise but require further validation.
Conclusions:
- Effective management of IAIs hinges on achieving adequate source control and judicious antimicrobial therapy tailored to individual risk factors.
- Further research, particularly randomized-controlled trials, is needed to address remaining controversies and refine treatment protocols.
- Early identification and aggressive management of high-risk patients are essential for improving survival and reducing morbidity.
Related Concept Videos
01:26Brain Abscess l: Introduction
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:27Acute Pyelonephritis I: Introduction
01:30Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
01:20Cholecystitis
01:26Urinary Tract Infection I: Introduction